ANI PHARMACEUTICALS, INC financials

  1. Home
  2. Financials
  3. ANIP
ANIP CIK 0001023024

Source: EDGAR filings · Built 2026-06-02T02:20:42Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 171.39M 47.78M 110.09M -40.08M 765.00K 9.13M
EBITDA 202.51M 68.31M 106.76M 21.69M 7.46M 28.62M
Working Capital 475.00M 334.00M 374.34M 244.82M 234.24M 91.76M
Net Debt 34.77M 180.01M 70.22M 240.36M 188.45M 178.12M
Gross Margin — — — — — 58.19%
Operating Margin 12.58% 0.10% 9.65% -11.15% -18.41% -7.68%
Net Margin 8.87% -3.01% 3.86% -15.14% -19.71% -10.82%
Return on Equity (ROE) 14.49% -4.59% 4.34% -15.27% -12.76% -11.52%
Return on Assets (ROA) 5.44% -1.44% 2.08% -6.30% -5.52% -4.89%
Current Ratio 2.71× 2.72× 3.57× 3.46× 3.68× 2.17×
Debt-to-Equity 0.59× 0.80× 0.67× 0.92× 0.86× 0.95×
Effective Tax Rate 18.22% 16.61% 5.50% 23.57% 24.00% 13.15%
Cash Conversion Ratio 2.36× -3.46× 6.33× 0.65× -0.08× -0.68×
Accruals Ratio -0.07× -0.06× -0.11× -0.02× -0.06× -0.08×
SBC % of Revenue 4.29% 4.78% 4.24% 4.61% 4.85% 6.21%
CapEx Coverage 13.39× 3.94× 13.41× -3.52× 1.30× 2.49×
Free Cash Flow Per Share $8.07 $2.47 $6.05 $-2.46 $0.06 $0.76

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 23.78× — 64.87× — — —
P/FCF 9.78× 22.35× 9.11× — 759.14× 38.05×
FCF Yield 10.23% 4.47% 10.97% — 0.13% 2.63%
EV / EBITDA 8.94× 19.72× 10.05× 41.24× 103.08× 18.36×
P/S 2.01× 1.90× 2.06× 2.07× 2.69× 1.67×
P/B 3.28× 2.89× 2.32× 2.09× 1.74× 1.78×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 883.37M 614.38M 486.82M 316.38M 216.14M 208.47M
Cost of Revenue — — — — — 87.16M
Research and Development Expense 51.66M 44.58M 34.29M 22.32M 11.37M 16.00M
Selling, General and Administrative Expense 317.75M 249.64M 161.70M 124.04M 84.29M 64.99M
Operating Income (Loss) 111.09M 584.00K 46.97M -35.28M -39.79M -16.02M
Income Tax Expense (Benefit) 17.45M -3.69M 1.09M -14.77M -13.46M -3.41M
Net Income (Loss) Attributable to Parent 78.34M -18.52M 18.78M -47.90M -42.60M -22.55M
Earnings Per Share, Basic $3.50 $-1.04 $0.86 $-3.05 $-3.40 $-1.88
Weighted Average Number of Shares Outstanding, Basic 20.05M 19.32M 18.00M 16.26M 12.60M 11.96M
Earnings Per Share, Diluted $3.32 $-1.04 $0.85 $-3.05 $-3.40 $-1.88
Weighted Average Number of Shares Outstanding, Diluted 21.23M 19.32M 18.19M 16.26M 12.60M 11.96M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 285.58M 144.86M 221.12M 48.23M 100.30M 7.86M
Assets, Current 753.12M 528.46M 519.82M 344.26M 321.77M 170.32M
Assets 1.44B 1.28B 904.42M 760.09M 771.60M 461.19M
Liabilities, Current 278.11M 194.45M 145.48M 99.44M 87.54M 78.56M
Long-term Debt, Excluding Current Maturities 291.84M 309.11M 284.82M 285.67M 286.52M 172.44M
Liabilities 899.65M 855.94M 446.82M 421.55M 412.86M 265.49M
Stockholders' Equity Attributable to Parent 540.72M 403.68M 432.75M 313.69M 333.89M 195.70M
Common Stock, Shares, Outstanding 22.49M 21.11M — — — —

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 185.22M 64.02M 118.96M -31.20M 3.32M 15.27M
Payments to Acquire Property, Plant, and Equipment 13.84M 16.24M 8.87M 8.88M 2.56M 6.13M
Net Cash Provided by (Used in) Investing Activities -34.32M -404.72M -18.51M -15.74M -105.48M -68.32M
Payments for Repurchase of Common Stock 12.21M 10.96M 4.99M 1.96M 890.00K 1.52M
Payments of Dividends 1.16M 1.63M 1.63M 1.63M 190.00K 0
Net Cash Provided by (Used in) Financing Activities -9.94M 264.94M 67.44M -5.13M 194.59M -1.44M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ANIP CIK 0001023024), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

MPLT

MapLight Therapeutics, Inc.

UNH

UnitedHealth Group Incorporated

CYH

COMMUNITY HEALTH SYSTEMS, INC.